Table 1.
Summary of individual studies included in the post hoc analysis
| Study | CONFIDENCE II | PROTECT I | STH I | STH II |
|---|---|---|---|---|
| Title | Effectiveness of home blood pressure monitoring and educational material for the control of mild to moderate hypertension with Coversyl® in a Canadian real-life routine medical practice II | Effectiveness of perindopril in the management of hypertension: impact of changes of physical activity on the control of blood pressure | Effectiveness of a support program designed to sensitize and assist patients with mild to moderate hypertension treated with perindopril to decrease their salt consumption (Shake the Habit I) | Effectiveness of a patient stress education program on blood pressure management in hypertensive patients treated with perindopril (Shake the Habit II—Managing Stress for Better Cardiovascular Health) |
| N | 13,886 | 15,665 | 12,697 | 9573 |
| Study period | 2008–2010 | 2009–2011 | 2010–2012 | 2012–2014 |
| Setting | General practitioners and community specialists across Canada | |||
| Inclusion criteria | Patients with mild to moderate hypertension, previously treated (not with perindopril) or not treated, defined as: 140 ≤ SBP ≤ 179 mmHg and 90 ≤ DBP ≤ 109 mmHg Diabetics: 130 ≤ SBP ≤ 179 mmHg and 80 ≤ DBP ≤ 109 mmHg If previously treated with ACEI or ARB and not controlled, switch to perindopril |
|||
| Non-inclusion criteria | Diagnosed with unstable coronary artery disease A history of myocardial infarction occurring < 1 month prior to study entry Uncontrolled, treated hypertension: SBP > 179 mmHg and/or DBP > 109 mmHg while on treatment |
|||
| Treatment | Perindopril 4 mg for 4 weeks, up to 8 mg if not controlled In the elderly (> 70 years) or in patients with renal impairment (creatine clearance < 60 mL/min), starting dose of perindopril was 2 mg, with up-titrations to optimal dose as necessary BP and safety assessment at inclusion (Visit 1), after 4 (± 2) weeks (Visit 2) and after 16 (± 2) weeks (Visit 3) |
|||
ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blockers, BP blood pressure, DBP diastolic blood pressure, SBP systolic blood pressure, STH Shake the Habit